Company name LaCrosse Footwear, Inc.
Stock ticker BOOT
Live stock price [stckqut]BOOT[/stckqut]
P/E compared to competitors Good
MANAGEMENT EXECUTION
Employee productivity Poor
Sales growth Poor
EPS growth Poor
P/E growth Poor
EBIT growth Poor
ANALYSIS
Confident Investor Rating Poor
Target stock price (TWCA growth scenario) $6.7
Target stock price (averages with growth) $9.59
Target stock price (averages with no growth) $10.12
Target stock price (manual assumptions) $12.68

“LaCrosse Footwear, Inc. (LaCrosse) is a developer and marketer of footwear
for work and outdoor users. The Company’s Danner and LaCrosse brands are
distributed domestically through a nationwide network of retailers and
distributors, and internationally through its Danish subsidiary, LaCrosse
Europe ApS, and through distributors and retailers in Asia, Europe and
Canada. Its work customers include people in law enforcement,
transportation, mining, oil and gas, military services and other
occupations. Outdoor customers include people active in hunting, hiking and
other outdoor recreational activities. On May 8, 2009, the Company announced
the formation of Environmentally Neutral Design Outdoor, Inc. (END). ”

Confident Investor comments: At this price and at this time, I do not think that a Confident Investor can confidently invest in this stock.

Company name Alexion Pharmaceuticals, Inc.
Stock ticker ALXN
Live stock price [stckqut]ALXN[/stckqut]
P/E compared to competitors Fair
MANAGEMENT EXECUTION
Employee productivity Good
Sales growth Good
EPS growth Good
P/E growth Poor
EBIT growth Good
ANALYSIS
Confident Investor Rating Good
Target stock price (TWCA growth scenario) $125.89
Target stock price (averages with growth) $204.31
Target stock price (averages with no growth) $126.37
Target stock price (manual assumptions) $114.35

“Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company,
which is engaged in the discovery, development and commercialization of
biologic therapeutic products aimed at treating patients with severe and
life-threatening disease states, including hematologic, kidney and
neurologic diseases, transplant rejection, cancer and autoimmune disorders.
Its marketed product Soliris (eculizumab) is a therapy approved for the
treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In
April 2009 and August 2009, the United States food and drug administration
(FDA) and the European Commission (E.C.), respectively, granted Soliris
orphan drug designation for the treatment of patients with atypical
Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island
manufacturing facility received regulatory approval from the E.C. for the
production of Soliris. ”

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in this stock.

From CNBC’s Mad Money:

Jim Cramer (text from Newsbusters.org):

The number you need to watch is the number that Scott Brown racks up against Martha Coakley in this amazing Massachusetts Senate race. I say amazing ’cause this was supposed to be a walkover. I mean, even a few weeks ago it was a lock for Democrat Coakley. But now everything’s up in the air, and a Brown win would be devastating for the president’s agenda. Let’s put Brown, okay, and I don’t mean UPS which I happen to own for my charitable trust. Particularly on healthcare reform, because Republican Brown has said he will definitely vote against the plan.

Brown in the Senate? That wrecks the 60-vote supermajority the Democrats have been counting on. It could spell the end for this almost year-long nightmare of a piece of healthcare legislation.

What does a Brown election mean larger than this? Well, first you’re going to get a knee-jerk rally in all the so-called penalized stocks — the HMOs, the drugs, the medical device-makers. I call it “knee-jerk,” though, because these stocks have been on fire for months. Look at Cramer fave WellPoint, or United Health. 52 week high. 52 week high. Merck, 52 week high. It’s been clear as a bell that the healthcare reform wasn’t going to affect most healthcare stocks. That’s versus what we thought last year.

More important, though, I think investors who are nervous about the dictatorship of the Pelosi proletariat will feel at ease, and we could have a gigantic rally off a Coakley loss and a Brown win. It will be a signal that a more pro-business, less pro-labor government could be in front of us. Hey, would you say it is more China like perhaps? No, we can never be as capitalist as the Communist Chinese. But how about a little bit less like the old Soviet Union? Yeah, that would be a bit more like it. Pelosi politburo emasculation! Everything from the banks, which are usually in the Democrats’ penalty box, or the oils which are despised by this administration for being carbon, could be propelled dramatically higher all of this Tuesday night.